Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Gee

Showing results (161-170 of 419) with videos related to

Pageof 42
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2017
Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell TransplantationIfigeneia Tzannou, Anastasia Papadopoulou, Swati Naik, et al.
The American Journal of Cardiology|January 26, 2025
Patient Characteristics, Management and Long-Term Outcomes of Patients With Cardiogenic Shock at a Large Safety Net HospitalEric J Hall, Colby R Ayers, Nicholas S Hendren, et al.
Circulation Research|December 7, 2017
TIME Trial: Effect of Timing of Stem Cell Delivery Following ST-Elevation Myocardial Infarction on the Recovery of Global and Regional Left Ventricular Function: Final 2-Year AnalysisJay H Traverse, Timothy D Henry, Carl J Pepine, et al.
Science Translational Medicine|July 31, 2020
The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myelomaPremal D Lulla, Ifigeneia Tzannou, Spyridoula Vasileiou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2021
T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical EffectsSpyridoula Vasileiou, Premal D Lulla, Ifigeneia Tzannou, et al.
Cytotherapy|January 3, 2016
International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trialsJacques Galipeau, Mauro Krampera, John Barrett, et al.
Blood|March 24, 2022
Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECsDavid H M Steffin, Ibrahim N Muhsen, LaQuisa C Hill, et al.
Blood|September 14, 2013
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 studyConrad Russell Y Cruz, Kenneth P Micklethwaite, Barbara Savoldo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 24, 2020
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin LymphomaCarlos A Ramos, Natalie S Grover, Anne W Beaven, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2019
T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T CellsNatalia Lapteva, Margaret Gilbert, Iulia Diaconu, et al.
Pageof 42

Showing results (161-170 of 419) with videos related to

Sort By:
Pageof 42
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2017
Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell TransplantationIfigeneia Tzannou, Anastasia Papadopoulou, Swati Naik, et al.
The American Journal of Cardiology|January 26, 2025
Patient Characteristics, Management and Long-Term Outcomes of Patients With Cardiogenic Shock at a Large Safety Net HospitalEric J Hall, Colby R Ayers, Nicholas S Hendren, et al.
Circulation Research|December 7, 2017
TIME Trial: Effect of Timing of Stem Cell Delivery Following ST-Elevation Myocardial Infarction on the Recovery of Global and Regional Left Ventricular Function: Final 2-Year AnalysisJay H Traverse, Timothy D Henry, Carl J Pepine, et al.
Science Translational Medicine|July 31, 2020
The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myelomaPremal D Lulla, Ifigeneia Tzannou, Spyridoula Vasileiou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2021
T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical EffectsSpyridoula Vasileiou, Premal D Lulla, Ifigeneia Tzannou, et al.
Cytotherapy|January 3, 2016
International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trialsJacques Galipeau, Mauro Krampera, John Barrett, et al.
Blood|March 24, 2022
Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECsDavid H M Steffin, Ibrahim N Muhsen, LaQuisa C Hill, et al.
Blood|September 14, 2013
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 studyConrad Russell Y Cruz, Kenneth P Micklethwaite, Barbara Savoldo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 24, 2020
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin LymphomaCarlos A Ramos, Natalie S Grover, Anne W Beaven, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2019
T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T CellsNatalia Lapteva, Margaret Gilbert, Iulia Diaconu, et al.
Pageof 42